Host-directed therapies for infectious diseases: Current status, recent progress, and future prospects

The Lancet Infectious Diseases

Volumn 16, Issue 4, 2016, Pages e47-e63

  Zumla, Alimuddin ^a,b   Rao, Martin ^c,d   Wallis, Robert S ^e   Kaufmann, Stefan H E ^f   Rustomjee, Roxana ^g   Mwaba, Peter ^h,i   Vilaplana, Cris ^j   Yeboah Manu, Dorothy ^k   Chakaya, Jeremiah ^l   Ippolito, Giuseppe ^m   Azhar, Esam ⁿ   Hoelscher, Michael ^o,p   Maeurer, Markus ^c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e AURUM INSTITUTE   (South Africa)

^f MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^g SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^h UNIVERSITY OF ZAMBIA   (Zambia)

ⁱ MINISTRY OF HEALTH   (Zambia)

^j FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^k University of Ghana   (Ghana)

^l KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^m NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

ⁿ KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^o LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^p German Center for Infection Research   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT; IMMUNOMODULATING AGENT; CYTOKINE; MONOCLONAL ANTIBODY; VITAMIN;

BACTERIAL INFECTION; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL THERAPY; EPIDEMIC; FUTUROLOGY; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION; INFLUENZA; INNATE IMMUNITY; MALARIA; MORBIDITY; MORTALITY; NON COMMUNICABLE DISEASE; NONHUMAN; NUTRITIONAL SUPPORT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS; VIRUS INFECTION; ZOONOSIS; BIOLOGICAL THERAPY; COMMUNICABLE DISEASES; DRUG RESISTANCE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; CELL- AND TISSUE-BASED THERAPY; COMMUNICABLE DISEASES; CYTOKINES; DRUG RESISTANCE; HOST-PATHOGEN INTERACTIONS; HUMANS; VITAMINS;

EID: 84962538329     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)00078-5     Document Type: Review

References (174)

1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385:117-171. GBD 2013 Mortality and Causes of Death Collaborators.
2. Hancock RE, Nijnik A, Philpott DJ Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 2012, 10:243-254.
3. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015, 385:1511-1518.
4. Rodríguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35:1493-1498. the CAPUCI Study Group.
5. Hanly PJ, Roberts D, Dobson K, Light RB Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. Lancet 1987, 1:351-354.
6. Ferrer M, Torres A, Baer R, Hernández C, Roca J, Rodriguez-Roisin R Effect of acetylsalicylic acid on pulmonary gas exchange in patients with severe pneumonia: a pilot study. Chest 1997, 111:1094-1100.
7. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997, 336:912-918. the Ibuprofen in Sepsis Study Group.
8. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006, 333:999.
9. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008, 31:611-617.
10. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007, 27:325-332.
11. Mortensen EM, Restrepo MI, Anzueto A, Pugh J The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005, 6:82.
12. Frost FJ, Petersen H, Tollestrup K, Skipper B Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007, 131:1006-1012.
13. Chalmers JD, Singanayagam A, Murray MP, Hill AT Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008, 121:1002. 07.e1.
14. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sørensen HT Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29900 patients. Arch Intern Med 2008, 168:2081-2087.
15. Liappis AP, Kan VL, Rochester CG, Simon GL The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001, 33:1352-1357.
16. Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006, 34:1080-1086.
17. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009, 18:269-275.
18. Douglas I, Evans S, Smeeth L Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011, 342:d1642.
19. Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011, 39:1871-1878.
20. Koh GC, Weehuizen TA, Breitbach K, et al. Glyburide reduces bacterial dissemination in a mouse model of melioidosis. PLoS Negl Trop Dis 2013, 7:e2500.
21. Karlström A, Heston SM, Boyd KL, Tuomanen EI, McCullers JA Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 2011, 204:1358-1366.
22. Waterer GW, Somes GW, Wunderink RG Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161:1837-1842.
23. Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004, 11:589-593.
24. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009, 33:153-159.
25. Mufson MA, Stanek RJ Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 1999, 107:34S-43S.
26. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36:389-395.
27. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-444. the International Pneumococcal Study Group.
28. Aspa J, Rajas O, Rodriguez de Castro F, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006, 27:1010-1019. the Pneumococcal Pneumonia in Spain Study Group.
29. Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 2005, 24:688-690.
30. Dwyer R, Ortqvist A, Aufwerber E, et al. Addition of a macrolide to an β-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006, 25:518-521.
31. Brown RB, Iannini P, Gross P, Kunkel M Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003, 123:1503-1511.
32. Metersky ML, Ma A, Houck PM, Bratzler DW Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007, 131:466-473.
33. Wroblewski LE, Peek RM, Wilson KT Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010, 23:713-739.
34. Guo L, Chen W, Zhu H, et al. Helicobacter pylori induces increased expression of the vitamin D receptor in immune responses. Helicobacter 2014, 19:37-47.
35. Skerry C, Scanlon K, Rosen H, Carbonetti NH Sphingosine-1-phosphate receptor agonism reduces Bordetella pertussis-mediated-lung pathology. J Infect Dis 2015, 211:1883-1886.
36. Halperin SA, Vaudry W, Boucher FD, Mackintosh K, Waggener TB, Smith B Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet. Pediatr Infect Dis J 2007, 26:79-81. the Pediatric Investigators Collaborative Network on Infections in Canada.
37. Scanlon KM, Skerry C, Carbonetti NH Novel therapies for the treatment of pertussis disease. Pathog Dis 2015, 73:ftv074.
38. Bruss JB, Siber GR Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Clin Diagn Lab Immunol 1999, 6:464-470.
39. Yedery R, Jerse A Augmentation of cationic antimicrobial peptide production with histone deacetylase inhibitors as a novel epigenetic therapy for bacterial infections. Antibiotics 2015, 4:44-61.
40. Leduc I, Jerse A Host-directed therapeutics as adjunctive therapy for antibiotic-resistant Neisseria gonorrhoeae. Sex Transm Infect 2015, 91(suppl 2). asbtr 38.
41. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004, 18:1101-1108.
42. Rasmussen TA, Tolstrup M, Moller HJ, et al. Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. Open Forum Infect Dis 2015, 2:ofv037.
43. Matalon S, Rasmussen TA, Dinarello CA Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 2011, 17:466-472.
44. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
45. Velu V, Shetty RD, Larsson M, Shankar EM Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology 2015, 12:14.
46. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006, 203:2281-2292.
47. Zhang Z, Fu J, Xu X, et al. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS 2013, 27:1283-1293.
48. Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013, 122:2965-2973.
49. Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013, 21:2113-2121.
50. Uhlin M, Gertow J, Uzunel M, et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012, 55:1064-1073.
51. Parida SK, Poiret T, Zhenjiang L, et al. T-cell therapy: options for infectious diseases. Clin Infect Dis 2015, 61(suppl 3):S217-S224.
52. Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy 2010, 30:554-561.
53. Ariza-Heredia EJ, Nesher L, Chemaly RF Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett 2014, 342:1-8.
54. Brestrich G, Zwinger S, Roemhild A, et al. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy. J Immunother 2009, 32:932-940.
55. Ljungman P Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 2004, 23:583-588.
56. Oliveira KG, Malta FM, Nastri AC, et al. Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3. Med Microbiol Immunol 2015, published online Aug 14. 10.1007/S00430-015-0431-0.
57. Ottosen S, Parsley TB, Yang L, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother 2015, 59:599-608.
58. Hovingh K, Besseling J, Kastelein J Efficacy and safety of mipomersen sodium (Kynamro). Expert Opin Drug Saf 2013, 12:569-579.
59. Reiner Ž Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol 2015, 12:565-575.
60. Gardiner D, Lalezari J, Lawitz E, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013, 8:e63818.
61. Foster GR Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010, 70:147-165.
62. Fedson DS Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013, 99:417-435.
63. Fedson DS Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009, 3:129-142.
64. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012, 205:13-19.
65. Fedson DS How will physicians respond to the next influenza pandemic?. Clin Infect Dis 2014, 58:233-237.
66. Chalkias S, Mackenzie MR, Gay C, et al. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl Infect Dis 2014, 16:141-144.
67. Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012, 206:1844-1851.
68. Fedson DS, Jacobson JR, Rordam OM, Opal SM Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. MBio 2015, 6:e00716.
69. Fedson DS, Rordam OM Treating Ebola patients: a 'bottom up' approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 2015, 36:80-84.
70. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola WHO, (accessed Feb 10, 2016). http://www.who.int/medicines/ebola-treatment/2015-0218_tables_of_ebola_drugs_updated.pdf.
71. Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 2013, 3:3365.
72. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003, 362:1953-1958.
73. Rothwell C, Lebreton A, Young Ng C, et al. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 2009, 389:8-19.
74. de Wispelaere M, LaCroix AJ, Yang PL The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol 2013, 87:7367-7381.
75. Krishnan MN, Garcia-Blanco MA Targeting host factors to treat West Nile and dengue viral infections. Viruses 2014, 6:683-708.
76. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015, 28:465-522.
77. Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009, 32(suppl 2):S223-S231.
78. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov 2016, published online Feb 12. 10.1038/nrd.2015.37.
79. Smith CM, Jerkovic A, Puy H, et al. Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites. Blood 2015, 125:534-541.
80. Mansour SC, de la Fuente-Nunez C, Hancock RE Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J Pept Sci 2015, 21:323-329.
81. Achtman AH, Pilat S, Law CW, et al. Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. Sci Transl Med 2012, 4:135ra64.
82. Collier MA, Gallovic MD, Peine KJ, et al. Delivery of host cell-directed therapeutics for intracellular pathogen clearance. Expert Rev Anti Infect Ther 2013, 11:1225-1235.
83. Chaurasia M, Pawar VK, Jaiswal AK, Dube A, Paliwal SK, Chourasia MK Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response. Int J Biol Macromol 2015, 79:27-36.
84. Goto H, Lindoso JA Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010, 8:419-433.
85. Bucheton B, MacLeod A, Jamonneau V Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections. Parasite Immunol 2011, 33:438-447.
86. Wang Y, Chen X, Cao W, Shi Y Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014, 15:1009-1016.
87. El Ridi RA, Tallima HA Novel therapeutic and prevention approaches for schistosomiasis: review. J Adv Res 2013, 4:467-478.
88. El Ridi R, Tallima H Vaccine-induced protection against murine schistosomiasis mansoni with larval excretory-secretory antigens and papain or type-2 cytokines. J Parasitol 2013, 99:194-202.
89. Global tuberculosis report 2015 2015, WHO, World Health Organization, Geneva, (accessed Feb 10, 2016). http://www.who.int/tb/publications/global_report/en/.
90. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP The immune response in tuberculosis. Annu Rev Immunol 2013, 31:475-527.
91. Zumla A, Rao M, Parida SK, et al. Inflammation and tuberculosis: host-directed therapies. J Intern Med 2015, 277:373-387.
92. Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med 2014, 6:263ra159.
93. Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460:103-107.
94. Beeson CC, Beeson GC, Schnellmann RG A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Anal Biochem 2010, 404:75-81.
95. Pirinen E, Cantó C, Jo YS, et al. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014, 19:1034-1041.
96. van der Windt GJ, Everts B, Chang CH, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 2012, 36:68-78.
97. Montoya D, Inkeles MS, Liu PT, et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med 2014, 6:250ra114.
98. Tobin DM, Roca FJ, Ray JP, Ko DC, Ramakrishnan L An enzyme that inactivates the inflammatory mediator leukotriene b4 restricts mycobacterial infection. PLoS One 2013, 8:e67828.
99. Mayer-Barber KD, Andrade BB, Oland SD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 511:99-103.
100. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013, 208:199-202.
101. Ivanyi J, Zumla A Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J Infect Dis 2013, 208:185-188.
102. Critchley JA, Young F, Orton L, Garner P Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13:223-237.
103. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:491-501.
104. Coussens AK, Wilkinson RJ, Martineau AR Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-hydroxy-vitamin D3. PLoS Pathog 2015, 11:e1005007.
105. Kulkarni NN, Yi Z, Huehnken C, Agerberth B, Gudmundsson GH Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: linkage to inflammatory and growth factor cytokines pathways. Mol Immunol 2015, 63:530-539.
106. Hall AG, Tilby MJ Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 1992, 6:163-173.
107. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
108. Henter JI, Chow CB, Leung CW, Lau YL Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet 2006, 367:870-873.
109. Henter JI, Palmkvist-Kaijser K, Holzgraefe B, Bryceson YT, Palmér K Cytotoxic therapy for severe swine flu A/H1N1. Lancet 2010, 376:2116.
110. Gupta S, Tyagi S, Bishai WR Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Antimicrob Agents Chemother 2015, 59:673-676.
111. Schiebler M, Brown K, Hegyi K, et al. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol Med 2015, 7:127-139.
112. Parihar SP, Guler R, Khutlang R, et al. Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 2014, 209:754-763.
113. Catron DM, Lange Y, Borensztajn J, Sylvester MD, Jones BD, Haldar K Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect Immun 2004, 72:1036-1042.
114. Napier RJ, Norris BA, Swimm A, et al. Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog 2015, 11:e1004770.
115. Daley P, Jagannathan V, John KR, et al. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2015, 15:528-534.
116. Rahman S, Rehn A, Rahman J, Andersson J, Svensson M, Brighenti S Pulmonary tuberculosis patients with a vitamin D deficiency demonstrate low local expression of the antimicrobial peptide LL-37 but enhanced FoxP3+ regulatory T cells and IgG-secreting cells. Clin Immunol 2015, 156:85-97.
117. Kaufmann SH, Lange C, Rao M, et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir Med 2014, 2:301-320.
118. Leung J, Suh WK The CD28-B7 family in anti-tumor immunity: emerging concepts in cancer immunotherapy. Immune Netw 2014, 14:265-276.
119. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
120. Singh A, Mohan A, Dey AB, Mitra DK Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis 2013, 208:603-615.
121. Jurado JO, Alvarez IB, Pasquinelli V, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 2008, 181:116-125.
122. Hassan SS, Akram M, King EC, Dockrell HM, Cliff JM PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS One 2015, 10:e0137646.
123. Ngiow SF, Teng MW, Smyth MJ Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011, 71:6567-6571.
124. Sada-Ovalle I, Chávez-Galán L, Torre-Bouscoulet L, et al. The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. J Immunol 2012, 189:5896-5902.
125. Phillips BL, Mehra S, Ahsan MH, Selman M, Khader SA, Kaushal D LAG3 expression in active Mycobacterium tuberculosis infections. Am J Pathol 2015, 185:820-833.
126. Nguyen LT, Ohashi PS Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol 2015, 15:45-56.
127. Wallis RS, van Vuuren C, Potgieter S Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009, 48:1429-1432.
128. Rossi JF, Lu ZY, Jourdan M, Klein B Interleukin-6 as a therapeutic target. Clin Cancer Res 2015, 21:1248-1257.
129. Ravimohan S, Tamuhla N, Steenhoff AP, et al. Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study. Lancet Infect Dis 2015, 15:429-438.
130. Datta M, Via LE, Kamoun WS, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci USA 2015, 112:1827-1832.
131. Oehlers SH, Cronan MR, Scott NR, et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature 2015, 517:612-615.
132. Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014, 2:108-122.
133. Zumla A, Maeurer M, Chakaya J, et al. Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov 2015, 14:511-512. the Host-Directed Therapies Network.
134. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902. the Hib and Pneumococcal Global Burden of Disease Study Team.
135. Hortal M, Camou T, Palacio R, Dibarboure H, Garcia A Ten-year review of invasive pneumococcal diseases in children and adults from Uruguay: clinical spectrum, serotypes, and antimicrobial resistance. Int J Infect Dis 2000, 4:91-95.
136. Zhang L, Li Z, Wan Z, Kilby A, Kilby JM, Jiang W Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection. Vaccine 2015, 33:4430-4436.
137. Morton B, Pennington SH, Gordon SB Immunomodulatory adjuvant therapy in severe community-acquired pneumonia. Expert Rev Respir Med 2014, 8:587-596.
138. Brouwer MC, McIntyre P, Prasad K, van de Beek D Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2013, 6. CD004405.
139. Voiriot G, Dury S, Parrot A, Mayaud C, Fartoukh M Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest 2011, 139:387-394.
140. Koh GC, Maude RR, Schreiber MF, et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis 2011, 52:717-725.
141. Parkin DM, Bray F, Ferlay J, Pisani P Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
142. Linz B, Balloux F, Moodley Y, et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature 2007, 445:915-918.
143. Bruner KM, Hosmane NN, Siliciano RF Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol 2015, 23:192-203.
144. Kaufmann SH, McMichael AJ Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 2005, 11(suppl):S33-S44.
145. Imami N, Gotch F Prospects for immune reconstitution in HIV-1 infection. Clin Exp Immunol 2002, 127:402-411.
146. Lai RP, Meintjes G, Wilkinson RJ HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome. Semin Immunopathol 2015, published online Sept 30. 10.1007/S00281-015-0532-2.
147. Goovaerts O, Jennes W, Massinga-Loembé M, et al. LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients. PLoS One 2013, 8:e81856. the TB-IRIS Study Group.
148. Rasmussen TA, Tolstrup M, Søgaard OS Reversal of latency as part of a cure for HIV-1. Trends Microbiol 2016, 24:90-97.
149. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12:1198-1202.
150. Mackall CL, Fry TJ, Gress RE Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011, 11:330-342.
151. Konforte D, Simard N, Paige CJ Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells. Virology 2008, 374:100-113.
152. Ghasemi F, Rostami S, Meshkat Z Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol 2015, 21:11984-12002.
153. Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, et al. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol 2008, 82:3154-3160.
154. Nakamoto N, Cho H, Shaked A, et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009, 5:e1000313.
155. Panel AIHG Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015, 62:932-954. the AASLD/IDSA HCV Guidance Panel.
156. Swaika A, Hammond WA, Joseph RW Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 2015, 67(2 pt A):4-17.
157. Nahmias Y, Goldwasser J, Casali M, et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 2008, 47:1437-1445.
158. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012, 55:1466-1473.
159. Ebola situation report WHO, (accessed Feb 26, 2016). http://apps.who.int/ebola/current-situation/ebola-situation-report-17-february-2016.
160. Winkler AM, Koepsell SA The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease. Curr Opin Hematol 2015, 22:521-526.
161. Blitvich BJ, Firth AE Insect-specific flaviviruses: a systematic review of their discovery, host range, mode of transmission, superinfection exclusion potential and genomic organization. Viruses 2015, 7:1927-1959.
162. Carabali M, Hernandez LM, Arauz MJ, Villar LA, Ridde V Why are people with dengue dying? A scoping review of determinants for dengue mortality. BMC Infect Dis 2015, 15:301.
163. WHO World malaria report 2014 2014, World Health Organization, Geneva, (accessed Feb 10, 2016). http://www.who.int/malaria/publications/world_malaria_report_2014/en/.
164. Cui L, Mharakurwa S, Ndiaye D, Rathod PK, Rosenthal PJ Antimalarial drug resistance: literature review and activities and findings of the ICEMR Network. Am J Trop Med Hyg 2015, 93(suppl):57-68.
165. Jacobs A Iron chelation therapy for iron loaded patients. Br J Haematol 1979, 43:1-5.
166. Kinra P, Dutta V Serum TNF alpha levels: a prognostic marker for assessment of severity of malaria. Trop Biomed 2013, 30:645-653.
167. Kwiatkowski D, Molyneux ME, Stephens S, et al. Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med 1993, 86:91-98.
168. Gurung P, Kanneganti TD Innate immunity against Leishmania infections. Cell Microbiol 2015, 17:1286-1294.
169. Seifert K, Juhls C, Salguero FJ, Croft SL Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate. Antimicrob Agents Chemother 2015, 59:5819-5823.
170. Firdessa R, Good L, Amstalden MC, et al. Pathogen- and host-directed antileishmanial effects mediated by polyhexanide (PHMB). PLoS Negl Trop Dis 2015, 9:e0004041.
171. Bern C Chagas' disease. N Engl J Med 2015, 373:456-466.
172. Franco JR, Simarro PP, Diarra A, Jannin JG Epidemiology of human African trypanosomiasis. Clin Epidemiol 2014, 6:257-275.
173. Weerakoon KG, Gobert GN, Cai P, McManus DP Advances in the diagnosis of human schistosomiasis. Clin Microbiol Rev 2015, 28:939-967.
174. Prendergast CT, Sanin DE, Cook PC, Mountford AP CD4+ T cell hyporesponsiveness after repeated exposure to Schistosoma mansoni larvae is dependent upon interleukin-10. Infect Immun 2015, 83:1418-1430.